Brimonidine Tartrate: A highly selective alpha-2 adrenergic receptor agonist. It lowers intraocular pressure through a dual mechanism: actively suppressing aqueous humor production from the ciliary body and enhancing uveoscleral outflow pathways.
Indications
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
Management of ocular hypertension
Note: This is an indicative Indication, please follow the doctors advise. Do not self medicate.
Dosage & Administration
Instill 1 drop into the inferior conjunctival cul-de-sac of the affected eye(s) as prescribed by the physician. Dosing frequency should be adjusted according to clinical response and severity.
Note: This is an indicative dosage, please follow the doctors advise. Do not self medicate.
References
1. Katz LJ, et al. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma. Curr Med Res Opin. 2002;18(4):231-238.
2. Toris CB, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999;127(4):407-412.
Warning: This information is only for the use of registered medical practitioners only.
Certified Manufacturing Standards
Disclaimer: This content is compiled from various references. We do not endorse any of it. Readers are advised not to self-medicate and to follow a doctor’s prescription and guidance.